Top 20 Prostate Cancer Drugs Market Analysis and Segment Forecasts to 2030
- Published: May, 2025
- Report ID: GVR-MT-100312
- Format: PDF/Excel databook
- No. of Pages/Datapoints: 90
- Report Coverage: 2024 - 2030
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Research Methodology
1.3. List of Secondary Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Top 20 Prostate Cancer Drugs Market: Product Business Analysis
3.1. Product Market Share, 2025 & 2030
3.2. Product Segment Dashboard
3.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
3.3.1. Zytiga
3.3.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
3.3.1.2. Impact of Generics/Biosimilars
3.3.1.3. Patent Expiry Analysis
3.3.1.4. Pricing and Reimbursement Scenario
3.3.1.5. Indication Approved
3.3.1.6. Competitive Scenario
3.3.2. Erleada
3.3.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
3.3.2.2. Impact of Generics/Biosimilars
3.3.2.3. Patent Expiry Analysis
3.3.2.4. Pricing and Reimbursement Scenario
3.3.2.5. Indication Approved
3.3.2.6. Competitive Scenario
3.3.3. Nubeqa
3.3.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
3.3.3.2. Impact of Generics/Biosimilars
3.3.3.3. Patent Expiry Analysis
3.3.3.4. Pricing and Reimbursement Scenario
3.3.3.5. Indication Approved
3.3.3.6. Competitive Scenario
3.3.4. Xofigo
3.3.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
3.3.4.2. Impact of Generics/Biosimilars
3.3.4.3. Patent Expiry Analysis
3.3.4.4. Pricing and Reimbursement Scenario
3.3.4.5. Indication Approved
3.3.4.6. Competitive Scenario
3.3.5. Lynparza
3.3.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
3.3.5.2. Impact of Generics/Biosimilars
3.3.5.3. Patent Expiry Analysis
3.3.5.4. Pricing and Reimbursement Scenario
3.3.5.5. Indication Approved
3.3.5.6. Competitive Scenario
3.3.6. Zoladex
3.3.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
3.3.6.2. Impact of Generics/Biosimilars
3.3.6.3. Patent Expiry Analysis
3.3.6.4. Pricing and Reimbursement Scenario
3.3.6.5. Indication Approved
3.3.6.6. Competitive Scenario
3.3.7. Casodex
3.3.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
3.3.7.2. Impact of Generics/Biosimilars
3.3.7.3. Patent Expiry Analysis
3.3.7.4. Pricing and Reimbursement Scenario
3.3.7.5. Indication Approved
3.3.7.6. Competitive Scenario
3.3.8. XTANDI
3.3.8.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
3.3.8.2. Impact of Generics/Biosimilars
3.3.8.3. Patent Expiry Analysis
3.3.8.4. Pricing and Reimbursement Scenario
3.3.8.5. Indication Approved
3.3.8.6. Competitive Scenario
3.3.9. Jevtana
3.3.9.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
3.3.9.2. Impact of Generics/Biosimilars
3.3.9.3. Patent Expiry Analysis
3.3.9.4. Pricing and Reimbursement Scenario
3.3.9.5. Indication Approved
3.3.9.6. Competitive Scenario
3.3.10. Decapeptyl
3.3.10.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
3.3.10.2. Impact of Generics/Biosimilars
3.3.10.3. Patent Expiry Analysis
3.3.10.4. Pricing and Reimbursement Scenario
3.3.10.5. Indication Approved
3.3.10.6. Competitive Scenario
3.3.11. Lupron
3.3.11.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
3.3.11.2. Impact of Generics/Biosimilars
3.3.11.3. Patent Expiry Analysis
3.3.11.4. Pricing and Reimbursement Scenario
3.3.11.5. Indication Approved
3.3.11.6. Competitive Scenario
3.3.12. Rubraca
3.3.12.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
3.3.12.2. Impact of Generics/Biosimilars
3.3.12.3. Patent Expiry Analysis
3.3.12.4. Pricing and Reimbursement Scenario
3.3.12.5. Indication Approved
3.3.12.6. Competitive Scenario
3.3.13. Pluvicto
3.3.13.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
3.3.13.2. Impact of Generics/Biosimilars
3.3.13.3. Patent Expiry Analysis
3.3.13.4. Pricing and Reimbursement Scenario
3.3.13.5. Indication Approved
3.3.13.6. Competitive Scenario
3.3.14. ORGOVYX
3.3.14.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
3.3.14.2. Impact of Generics/Biosimilars
3.3.14.3. Patent Expiry Analysis
3.3.14.4. Pricing and Reimbursement Scenario
3.3.14.5. Indication Approved
3.3.14.6. Competitive Scenario
3.3.15. FIRMAGON
3.3.15.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
3.3.15.2. Impact of Generics/Biosimilars
3.3.15.3. Patent Expiry Analysis
3.3.15.4. Pricing and Reimbursement Scenario
3.3.15.5. Indication Approved
3.3.15.6. Competitive Scenario
3.3.16. XGEVA
3.3.16.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
3.3.16.2. Impact of Generics/Biosimilars
3.3.16.3. Patent Expiry Analysis
3.3.16.4. Pricing and Reimbursement Scenario
3.3.16.5. Indication Approved
3.3.16.6. Competitive Scenario
3.3.17. Prolia
3.3.17.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
3.3.17.2. Impact of Generics/Biosimilars
3.3.17.3. Patent Expiry Analysis
3.3.17.4. Pricing and Reimbursement Scenario
3.3.17.5. Indication Approved
3.3.17.6. Competitive Scenario
3.3.18. Zometa
3.3.18.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
3.3.18.2. Competitive Scenario
3.3.18.3. Impact of Generics/Biosimilars
3.3.18.4. Patent Expiry Analysis
3.3.18.5. Pricing and Reimbursement Scenario
3.3.18.6. Indication Approved
3.3.18.7. Competitive Scenario
Chapter 4. Top 20 Prostate Cancer Drugs Market: Regional Estimates & Trend Analysis
4.1. Regional Market Share Analysis, 2025 & 2030
4.2. Regional Market Dashboard
4.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
4.4. North America
4.4.1. North America Top 20 Prostate Cancer Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
4.4.2. U.S.
4.4.2.1. U.S. Top 20 Prostate Cancer Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.3. Canada
4.4.3.1. Canada Top 20 Prostate Cancer Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.4. Mexico
4.4.4.1. Mexico Top 20 Prostate Cancer Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Europe
4.5.1. Europe Top 20 Prostate Cancer Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.2. UK
4.5.2.1. UK Top 20 Prostate Cancer Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.3. Germany
4.5.3.1. Germany Top 20 Prostate Cancer Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.4. France
4.5.4.1. France Top 20 Prostate Cancer Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.5. Italy
4.5.5.1. Italy Top 20 Prostate Cancer Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.6. Spain
4.5.6.1. Spain Top 20 Prostate Cancer Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.7. Denmark
4.5.7.1. Denmark Top 20 Prostate Cancer Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.8. Sweden
4.5.8.1. Sweden Top 20 Prostate Cancer Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.9. Norway
4.5.9.1. Norway Top 20 Prostate Cancer Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Asia Pacific
4.6.1. Asia Pacific Top 20 Prostate Cancer Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.2. Japan
4.6.2.1. Japan Top 20 Prostate Cancer Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.3. China
4.6.3.1. China Top 20 Prostate Cancer Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.4. India
4.6.4.1. India Top 20 Prostate Cancer Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.5. Australia
4.6.5.1. Australia Top 20 Prostate Cancer Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.6. South Korea
4.6.6.1. South Korea Top 20 Prostate Cancer Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.7. Thailand
4.6.7.1. Thailand Top 20 Prostate Cancer Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Latin America
4.7.1. Latin America Top 20 Prostate Cancer Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7.2. Brazil
4.7.2.1. Japan Top 20 Prostate Cancer Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7.3. Argentina
4.7.3.1. China Top 20 Prostate Cancer Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8. Middle East and Africa
4.8.1. Middle East and Africa Top 20 Prostate Cancer Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8.2. South Africa
4.8.2.1. South Africa Top 20 Prostate Cancer Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8.3. Saudi Arabia
4.8.3.1. Saudi Arabia Top 20 Prostate Cancer Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8.4. UAE
4.8.4.1. UAE Top 20 Prostate Cancer Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8.5. Kuwait
4.8.5.1. Kuwait Top 20 Prostate Cancer Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global Prostate Cancer: Top 20 Drug Sales Market, by Region, 2018 - 2030 (USD Million)
Table 4 Global Prostate Cancer: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 5 Global Prostate Cancer: Top 20 Drug Sales Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 6 North America Prostate Cancer: Top 20 Drug Sales Market, by Country, 2018 - 2030 (USD Million)
Table 7 North America Prostate Cancer: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 8 North America Prostate Cancer: Top 20 Drug Sales Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 9 U.S. Prostate Cancer: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 10 U.S. Prostate Cancer: Top 20 Drug Sales Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 11 Canada Prostate Cancer: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 12 Canada Prostate Cancer: Top 20 Drug Sales Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 13 Mexico Prostate Cancer: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 14 Mexico Prostate Cancer: Top 20 Drug Sales Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 15 Europe Prostate Cancer: Top 20 Drug Sales Market, by Country, 2018 - 2030 (USD Million)
Table 16 Europe Prostate Cancer: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 17 Europe Prostate Cancer: Top 20 Drug Sales Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 18 UK Prostate Cancer: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 19 UK Prostate Cancer: Top 20 Drug Sales Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 20 Germany Prostate Cancer: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 21 Germany Prostate Cancer: Top 20 Drug Sales Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 22 France Prostate Cancer: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 23 France Prostate Cancer: Top 20 Drug Sales Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 24 Italy Prostate Cancer: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 25 Italy Prostate Cancer: Top 20 Drug Sales Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 26 Spain Prostate Cancer: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 27 Spain Prostate Cancer: Top 20 Drug Sales Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 28 Norway Prostate Cancer: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 29 Norway Prostate Cancer: Top 20 Drug Sales Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 30 Sweden Prostate Cancer: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 31 Sweden Prostate Cancer: Top 20 Drug Sales Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 32 Denmark Prostate Cancer: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 33 Denmark Prostate Cancer: Top 20 Drug Sales Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 34 Asia-Pacific Prostate Cancer: Top 20 Drug Sales Market, by Country, 2018 - 2030 (USD Million)
Table 35 Asia-Pacific Prostate Cancer: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 36 Asia-Pacific Prostate Cancer: Top 20 Drug Sales Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 37 Japan Prostate Cancer: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 38 Japan Prostate Cancer: Top 20 Drug Sales Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 39 China Prostate Cancer: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 40 China Prostate Cancer: Top 20 Drug Sales Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 41 India Prostate Cancer: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 42 India Prostate Cancer: Top 20 Drug Sales Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 43 Australia Prostate Cancer: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 44 Australia Prostate Cancer: Top 20 Drug Sales Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 45 South Korea Prostate Cancer: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 46 South Korea Prostate Cancer: Top 20 Drug Sales Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 47 Thailand Prostate Cancer: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 48 Thailand Prostate Cancer: Top 20 Drug Sales Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 49 Latin America Prostate Cancer: Top 20 Drug Sales Market, by Country, 2018 - 2030 (USD Million)
Table 50 Latin America Prostate Cancer: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 51 Latin America Prostate Cancer: Top 20 Drug Sales Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 52 Brazil Prostate Cancer: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 53 Brazil Prostate Cancer: Top 20 Drug Sales Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 54 Argentina Prostate Cancer: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 55 Argentina Prostate Cancer: Top 20 Drug Sales Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 56 Middle East & Africa Prostate Cancer: Top 20 Drug Sales Market, by Country, 2018 - 2030 (USD Million)
Table 57 Middle East & Africa Prostate Cancer: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 58 Middle East & Africa Prostate Cancer: Top 20 Drug Sales Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 59 South Africa Prostate Cancer: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 60 South Africa Prostate Cancer: Top 20 Drug Sales Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 61 Saudi Arabia Prostate Cancer: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 62 Saudi Arabia Prostate Cancer: Top 20 Drug Sales Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 63 UAE Prostate Cancer: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 64 UAE Prostate Cancer: Top 20 Drug Sales Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 65 Kuwait Prostate Cancer: Top 20 Drug Sales Market, by Product, 2018 - 2030 (USD Million)
Table 66 Kuwait Prostate Cancer: Top 20 Drug Sales Market, by Route of Administration, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Prostate Cancer: Top 20 Drug Sales market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Value chain-based sizing & forecasting
Fig. 6 Market formulation & validation
Fig. 7 Market snapshot
Fig. 8 Product and Route of Administration outlook (USD Million)
Fig. 9 Competitive landscape snapshot
Fig. 10 Market dynamics
Fig. 11 Porter’s five forces analysis
Fig. 12 PESTLE analysis
Fig. 13 Prostate Cancer: Top 20 Drug Sales market: Product outlook and key takeaways
Fig. 14 Prostate Cancer: Top 20 Drug Sales market: Product movement analysis
Fig. 15 Zytiga market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 16 Erleada market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 17 Nubeqa market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 18 Pluvicto market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 Decapeptylmarket estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Zoladex market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Zytiga market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Prolia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Jevtana market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Lupron market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 XGEVA market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Xofigo market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 ORGOVYX market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Rubraca market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Lynparza market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 FIRMAGON market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Casodex market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Zometa market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Prostate Cancer: Top 20 Drug Sales market: Route of administration outlook and key takeaways
Fig. 34 Prostate Cancer: Top 20 Drug Sales market: Route of administration movement analysis
Fig. 35 Topical market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Oral market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Prostate Cancer: Top 20 Drug Sales market revenue, by region, 2025 & 2030 (USD Billion)
Fig. 39 Regional marketplace: Key takeaways
Fig. 40 North America Prostate Cancer: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 41 Key country dynamics: North America
Fig. 42 U.S. Prostate Cancer: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 43 Canada Prostate Cancer: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 44 Mexico Prostate Cancer: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 45 Europe Prostate Cancer: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 46 Key country dynamics: Europe
Fig. 47 UK Prostate Cancer: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 48 Germany Prostate Cancer: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 49 France Prostate Cancer: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 50 Italy Prostate Cancer: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 51 Spain Prostate Cancer: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 52 Norway Prostate Cancer: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 53 Sweden Prostate Cancer: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 54 Denmark Prostate Cancer: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 55 Asia-Pacific Prostate Cancer: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 56 Key country dynamics: Asia-Pacific
Fig. 57 Japan Prostate Cancer: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 58 China Prostate Cancer: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 59 India Prostate Cancer: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 60 Australia Prostate Cancer: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 61 South Korea Prostate Cancer: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 62 Thailand Prostate Cancer: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 63 Rest of Asia-Pacific Prostate Cancer: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 64 Latin America Prostate Cancer: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 65 Key country dynamics: Latin America
Fig. 66 Brazil Prostate Cancer: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 67 Argentina Prostate Cancer: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 68 Rest of Latin America Prostate Cancer: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 69 Middle East & Africa (MEA) Prostate Cancer: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 70 Key country dynamics: MEA
Fig. 71 Saudi Arabia Prostate Cancer: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 72 UAE Prostate Cancer: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 73 Kuwait Prostate Cancer: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 74 South Africa Prostate Cancer: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 75 Rest of MEA Prostate Cancer: Top 20 Drug Sales market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 76 Company categorization
Fig. 77 Strategy mapping
Fig. 78 Company market position analysis
Fig. 79 Competitive landscape assessment
Fig. 80 Strategic framework analysis
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.